openPR Logo
Press release

US Transdermal Patch Market Outlook 2020

06-29-2017 06:04 AM CET | Health & Medicine

Press release from: Kuick Resarch

The last two decades have witnessed multiple innovations and commercialization of new medical agents and drug delivery mechanism. These innovations in drug delivery systems have not only enabled the successful implementation of many of these novel pharmaceuticals products such as transdermal patches, but have also permitted the development of new medical treatments with existing drugs. The need of more innovation in field of transdermal drug delivery system is still huge and will remain so in the upcoming years of the medicinal world.

If taken a look at the medicinal markets of the world, indeed they are now replete with medications designed to ease and cure the symptoms associated with thousands of conditions. Traditional medication delivery methods, such as pills, capsules, liquids, powders, and intravenous needles, are often inefficient or invasive and can lead to undesirable side effects.

Download Report:

https://www.kuickresearch.com/report-US-Transdermal-Patch-Market-Outlook-2020.php

Amongst the newer methodologies for administration of medicines is the use of transdermal approaches, including gels and patches for the treatment of many of the more common ailments. The creation of transdermal delivery systems has been one of the most important innovations, offering a number of advantages over the oral route.

Transdermal patches comprise a method of delivering medication through the skin in a non-invasive manner. During transdermal drug delivery, a patch is simply applied on the epidermal layer of a patient’s skin. The patch is modulated to contain the medication prescribed to the patient and is designed in such a way that the medication permeates the skin in a controlled fashion thus attaining more steady levels of the drug in the body.

Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.

The market for transdermal products has skyrocketed since its innovation and is likely to continue for the foreseeable future. An increasing number of Transdermal drug delivery (TDD) products continue to deliver real therapeutic benefit to patients around the world. The FDA approved a total of 32 transdermal products over the past 20 years, the majority of which use passive transport that allows the drug to be continually absorbed into the skin via natural processes.

Technologies behind transdermal patches are improving continuously and have been introduced for different indication in US. They have been introduced for new indications for which no transdermal product was available allowing them to occupy major market shares. Increase in demand for better therapeutics at affordable prices is expected to be the main factor behind their growth in US market. Improved material science, advanced manufacturing capabilities and high acceptance rates will further propel growth in this segment. However, some immediate issues like lesser coverage of indications have yet to be overcome in coming years. Another issue is technology related, which has definitely improved, but needs to be improved in order to come forth with diseases like HIV infection. Overall, transdermal patch market in US is expected to grow continuously reflecting optimistic future.

“US Transdermal Patch Market Outlook 2020” Report Highlights:

* US Transdermal Patch Market Overview
* Generic & Branded Transdermal Patches
* US Transdermal Patch Market: Value Chain Analysis
* US Transdermal Patch Contract Manufacturing Organization
* US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
* US Transdermal Patch Clinical Pipeline: 55 Patches
* Majority Patches in Preclinical Phase: 23 Patches
* Marketed Transdermal Patch Clinical Insight by Company & Indication
* Marketed Transdermal Patches in US: 32 Patches

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Transdermal Patch Market Outlook 2020 here

News-ID: 600806 • Views:

More Releases from Kuick Resarch

Targeted Alpha Therapy Market
Targeted Alpha Therapy Market
Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028 Report Highlights: • Global Targeted Alpha Therapy Market Insight By Region • Approved Targeted Alpha Therapy Dosage & Pricing Insight • Number Of Targeted Alpha Therapy In Clinical Trials: > 20 Drugs • Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase • Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication • Targeted Alpha Therapy Proprietary Technology Platform Insights By
Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions: • Global Cancer Antibody Drug Conjugates Market: 2020 - 2030 • Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030 • Approved Cancer Antibody Drug Conjugates: 16 Drugs • Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis • Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs • Cancer Antibody Drug Conjugates Clinical
Cancer Peptide Drugs Market
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights: • Global Peptide Cancer Drug Market Insight By Region & Indication • Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion • Approved Peptide Cancer Drugs: > 30 Drugs • Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis • Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase • Insight On Peptide Cancer Drugs In Clinical Trials: >
Bispecific Antibody Drug Conjugates Development
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,

All 5 Releases


More Releases for Transdermal

Transdermal Skin Patches: Market Trends and Forecast
The transdermal skin patches market size has grown steadily in recent years. It will grow from $7.36 billion in 2023 to $7.67 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing incidence of cardiovascular diseases, strong economic growth in emerging markets, the increase in pharmaceutical r&d expenditure and increased healthcare expenditure. The transdermal skin patches
Global Transdermal Drug Delivery Systems Market 2023 Industry Data - Transdermal …
Global Transdermal Drug Delivery Systems market report by The Brainy Insights provides readers with a descriptive outlook of the market at regional as well as country levels. The historical data in the report provides an accurate analysis of the market in the forecast period (2023-2032). Market was studied in-depth to provide an overview of the market by value chain analysis and SWOT analysis. The study was done by doing a qualitative and
Global Transdermal Skin Patches Market | Global Transdermal Skin Patches Industr …
The transdermal skin patches market comprises of sales of transdermal skin patches products and connected services utilize to deliver medicine to the human body through patches. The Transdermal skin patches comprise the usage of adhesive patches made up of polymers that comprises drugs. The drug from such patches are absorbed into the body and ultimately into the blood stream disregarding the drug delivery through pill, or injections. According to the
Transdermal Patch Market Report 2018: Segmentation by Product (Fentanyl Transder …
Global Transdermal Patch market research report provides company profile for Actavis, Mundipharma, Henan Lingrui Pharmaceutical, Changzhou Siyao, Rfl Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018
US Transdermal Patch Market US Transdermal Sales Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Transdermal Patch 2. Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch 3. Why There Exist Need for Transdermal Patches? 4. Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of
Transdermal Patch Market Transdermal Patch Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Transdermal Patch Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch Why There Exist Need for Transdermal Patches? Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of Transdermal Patch 4.3